International Journal of Medical Sciences

Impact factor
2.284

18 August 2018

ISSN 1449-1907 News feeds of published articles

Manuscript login | Account

open access Global reach, higher impact

Theranostics

Journal of Cancer

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Oncomedicine

Journal of Biomedicine

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2017; 14(5):419-424. doi:10.7150/ijms.18555

Research Paper

High Level of Plasma EGFL6 Is Associated with Clinicopathological Characteristics in Patients with Oral Squamous Cell Carcinoma

Chun-Yi Chuang1, 2, Mu-Kuan Chen3, 4, 5, Ming-Ju Hsieh4, 5, 6, Chia-Ming Yeh3, 4, 5, Chiao-Wen Lin7, 8, Wei-En Yang5, 9, Shun-Fa Yang5, 9, Ying-Erh Chou1, 9✉

1. School of Medicine, Chung Shan Medical University, Taichung, Taiwan;
2. Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan;
3. Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan;
4. Cancer Research Center, Changhua Christian Hospital, Changhua, Taiwan;
5. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan;
6. Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan;
7. Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan;
8. Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan;
9. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.

Abstract

EGF-like domain 6 (EGFL6), a member of the epidermal growth factor (EGF) repeat protein superfamily, is a secreted protein that promotes endothelial cell migration and angiogenesis. The current study investigated the association between the clinicopathological characteristics and plasma level of EGFL6 in patients with oral squamous cell carcinoma (OSCC). We measured the plasma EGFL6 levels of 392 OSCC patients by using a commercial enzyme-linked immunosorbent assay. We also analyzed EGFL6 mRNA levels of 328 OSCC patients from The Cancer Genome Atlas (TCGA) dataset. The results showed that plasma EGFL6 levels were significantly higher in patients with OSCC than in healthy controls (p < 0.001). Similar results were observed for the TCGA bioinformatics database. Moreover, plasma EGFL6 levels were significantly higher in the patients with advanced T status (p = 0.002), distant metastasis (p = 0.001), and higher TNM stage (p=0.033). In conclusion, our results suggest that plasma level of EGFL6 may be useful to assess disease progression, and especially advanced T status and higher TNM stage in patients with OSCC.

Keywords: EGFL6, oral squamous cell carcinoma, biomarker.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Chuang CY, Chen MK, Hsieh MJ, Yeh CM, Lin CW, Yang WE, Yang SF, Chou YE. High Level of Plasma EGFL6 Is Associated with Clinicopathological Characteristics in Patients with Oral Squamous Cell Carcinoma. Int J Med Sci 2017; 14(5):419-424. doi:10.7150/ijms.18555. Available from http://www.medsci.org/v14p0419.htm